CDSCO To Crack Down On Pharma Companies Not Using Barcodes

New Delhi: India’s drug regulatory authority will take action against Pharma companies that have failed to implement Barcodes or QR Codes on top 300 Medicine Brands.

The drug regulator is also considering setting up a joint task force for fighting the menace of spurious and adulterated drugs in the country, people in the know told ET.

In a recent meeting the drug regulator has asked states for “strict implementation” of barcodes. In a bid to weed out spurious drugs, the regulator had made it mandatory for the companies to have a barcode  on its label so that information such as manufacturing licence and batch number can be accessed upon scanning.

The top 300 brands of drugs included widely used analgesics, pain relievers, anti-platelet, vitamin supplements, blood-sugar lowering medicines and contraceptive tablets. “The move was to ensure authenticity of drugs and enable tracing,” added the person.

The brands identified by the National Pharmaceutical Pricing Authority (NPPA) include Dolo, Saridon Fabiflu, Ecosprin, Limcee, Sumo, Calpol, Corex syrup, Unwanted 72 and Thyronorm. They were shortlisted on the basis of their moving annual turnover value as per data from market research firm Pharmatrac.

Prior to this, the health ministry had asked the department of pharmaceuticals (DoP) to shortlist top 300 drugs so that necessary amendments can be made in the drug rules for its implementation.

QR codes can help in tracking and tracing the origin of drugs and minimise the chances of spurious, substandard or counterfeit drugs reaching patients.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit